✦ LIBER ✦

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECTION): a multicentre, randomised, double-blind extension trial

✍ Scribed by Giovannoni, Gavin; Gold, Ralf; Selmaj, Krzysztof; Havrdova, Eva; Montalban, Xavier; Radue, Ernst-Wilhelm; Stefoski, Dusan; McNeill, Manjit; Amaravadi, Lakshmi; Sweetser, Marianne; Elkins, Jacob; O'Neill, Gilmore

Book ID: 123105567
Publisher: The Lancet
Year: 2014
Tongue: English
Weight: 334 KB
Volume: 13
Category: Article
ISSN: 1474-4465
DOI: 10.1016/S1474-4422(14)70039-0

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Daclizumab high-yield process in relapsi

Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial

✍ Gold, Ralf; Giovannoni, Gavin; Selmaj, Krzysztof; Havrdova, Eva; Montalban, Xavi 📂 Article 📅 2013 🏛 The Lancet 🌐 English ⚖ 416 KB

Methylprednisolone in combination with i

Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial

✍ Mads Ravnborg; Per Soelberg Sørensen; Magnus Andersson; Elisabeth G Celius; Pete 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 374 KB

Daclizumab in active relapsing multiple

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta

✍ Daniel Wynn; Michael Kaufman; Xavier Montalban; Timothy Vollmer; Jack Simon; Jac 📂 Article 📅 2010 🏛 The Lancet 🌐 English ⚖ 456 KB

Efficacy and safety of oral fumarate in

Efficacy and safety of oral fumarate in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ Ludwig Kappos; Ralf Gold; David H Miller; David G MacManus; Eva Havrdova; Volker 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 209 KB

Safety and efficacy of fingolimod in pat

Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial

✍ Calabresi, Peter A; Radue, Ernst-Wilhelm; Goodin, Douglas; Jeffery, Douglas; Ram 📂 Article 📅 2014 🏛 The Lancet 🌐 English ⚖ 290 KB

Effect of laquinimod on MRI-monitored di

Effect of laquinimod on MRI-monitored disease activity in patients with relapsing-remitting multiple sclerosis: a multicentre, randomised, double-blind, placebo-controlled phase IIb study

✍ G Comi; A Pulizzi; M Rovaris; O Abramsky; T Arbizu; A Boiko; R Gold; E Havrdova; 📂 Article 📅 2008 🏛 The Lancet 🌐 English ⚖ 143 KB